6 news items
Scilex Holding Announce Final Court Approval Settlement Agreement With Takeda Pharmaceuticals To Resolve The Paragraph IV Patent Infringement Lawsuit
SCLX
TAK
14 May 24
and chronic pain, today announced that the 45-day review period for the U.S. Federal Trade Commission and U.S. Department of Justice to comment
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
TAK
18 Apr 24
).8 Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of the gastrointestinal tract
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
TAK
27 Mar 24
IBD is a lifelong condition characterized by chronic inflammation in the gastrointestinal
Takeda Announces Approval Of ADZYNMA Intravenous Injection 1500 In Japan For Patients With Congenital Thrombotic Thrombocytopenic Purpura
TAK
26 Mar 24
cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic
Takeda Announces U.S. FDA Approval Of Supplemental New Drug Application For ICLUSIG In Adult Patients With Newly Diagnosed Ph+ ALL
TAK
19 Mar 24
are indicated or T315I-positive Ph+ ALL, chronic-phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors, accelerated phase (AP
rue86
TAK
13 Mar 24
evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP
- Prev
- 1
- Next